Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far

Anne Clavreul1,2
Milad Pourbaghi-Masouleh2,3
Emilie Roger4
Philippe Menei1,2

1Department of Neurosurgery, CHU, Angers, France;
2CRCINA, INSERM, University of Nantes, University of Angers, Angers, France;
3Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University of Nottingham, Nottingham, UK;
4MINT, INSERM 1066, CNRS 6021, University of Angers, Angers, France

Abstract: Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment. There are several possible reasons for this limited efficacy, including VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic factor delivery to the tumor. Efforts have been made to overcome these limitations by identifying new angiogenesis inhibitors that target angiogenesis through different mechanisms of action without inducing tumor invasion, and through the development of viral and nonviral delivery methods to improve antiangiogenic activity. Herein, we describe the nonviral methods, including convection-enhanced delivery devices, implantable polymer devices, nanocarriers, and cellular vehicles, to deliver antiangiogenic factors. We focus on those evaluated in intracranial (orthotopic) animal models of GB, the most relevant models of this disease, as they reproduce the clinical scenario of tumor progression and therapy response encountered in GB patients.

Keywords: antiangiogenic factors, delivery methods, glioblastoma, convection-enhanced delivery devices, implantable polymer devices, nanocarriers, cellular vehicles

Introduction
Glioblastoma (GB) is the commonest and most aggressive primary brain tumor. Despite standard treatment including resection and radiotherapy plus concomitant and adjuvant temozolomide (TMZ), prognosis remains poor, with a median survival of 12–18 months after diagnosis.1,2

GB is highly invasive and is characterized by a high rate of cell proliferation, heterogeneity, necrosis, and an abnormal angiogenic vasculature. This abnormal vasculature contributes to the development of high interstitial fluid pressure within the tumor, preventing the effective delivery of chemotherapy agents to the tumor tissue. This dysfunctional vasculature can also hinder tumor oxygenation, thereby promoting resistance to radiotherapy.3

This key role of the vasculature in treatment resistance has led to interest in GB treatment strategies that interfere with angiogenesis or destroy the existing tumor blood vessel network. The vascular abnormalities observed in GB have been attributed principally to the very high levels of vascular endothelial growth factor (VEGF) produced by tumor cells and tumor-associated stromal and inflammatory cells. VEGF is an angiogenic mitogen that operates by binding to VEGF receptors, triggering endothelial cell proliferation, migration, and the formation of new vessels. The possibility...
of blocking this key process with angiogenesis inhibitors has raised hopes that it might be possible to inhibit tumor growth, thereby prolonging patient survival. However, Phase III clinical trials involving the systemic administration of the anti-VEGF-A antibody bevacizumab (Avastin) or a pan-VEGF receptor (VEGFR)-2 tyrosine kinase inhibitor (cediranib, Recentin) in patients with recurrent or newly diagnosed GB have yielded disappointing results. These agents alleviated symptoms and made it possible to reduce steroid dose, but no improvement in overall survival relative to standard treatment was observed. There are several possible reasons for this limited efficacy, including VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic factor delivery to the tumor.

These limitations have led to an intensification of efforts to discover new angiogenesis inhibitors targeting this process via more than one mechanism without inducing tumor invasion, and efforts to develop viral and nonviral delivery methods for local or systemic treatment to improve antiangiogenic activity. Many studies have evaluated these methods in subcutaneous (heterotopic) models of GB. However, these models do not take into account tissue-specific constraints, such as the effects of the blood–brain barrier (BBB) and the brain microenvironment associated with GB therapy. Studies in such models may, therefore, lead to an overinterpretation of the effects of the engineered delivery methods. In this review, we present the local or systemic nonviral delivery methods used to increase the activity of antiangiogenic factors, focusing in particular on those evaluated in intracranial (orthotopic) animal models of GB, which are the most relevant, as they closely resemble the human disease in terms of the clinical scenario of tumor progression and treatment response.

**Angiogenesis and GB**

The tumor requires new blood vessels to provide it with oxygen and nutrients once its volume increases beyond 1–2 mm$^3$. Angiogenesis increases the blood supply to the tumor through the development of new vessels from the pre-existing vasculature (Figure 1). This process is regulated by the balance between proangiogenic factors, such as VEGF...
and fibroblast growth factor-2 (FGF-2), and antiangiogenic factors, such as angiostatin, angiopoietin 2, and endostatin. These factors may be released by the tumor itself or by the surrounding tissues. The blood supply may also be increased by vascular co-option, vascular intussusception, vasculogenic mimicry, and bone marrow-derived vasculogenesis (Figure 1). Briefly, vascular co-option involves the infiltration of tumor cells into normal tissue and adoption of the pre-existing vasculature. Vessel intussusception is the formation of new vessels by the enlargement and bifurcation of existing vessels. Vasculogenic mimicry is a process in which GB stem-like cells (GSCs) contribute to the formation of tumor blood vessels by differentiating into endothelial cells or pericytes. Bone marrow-derived vasculogenesis involves the recruitment of endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), or hematopoietic stem cells to the tumor, their integration into the vessel wall, and their terminal differentiation into endothelial cells (Figure 1).

The new tumor vasculature is leaky, circuitous, dilated, and saccular, with a haphazard pattern of interconnection. In particular, the endothelial cells lining the new vessels have an irregular, disorganized morphology and are often poorly connected or overlap. The cells supporting the endothelial cells, the pericytes, are loosely attached or absent, and the basement membrane may be abnormally thick or entirely absent. The physiological consequences of these vascular abnormalities include temporal and spatial heterogeneity in tumor blood flow and oxygenation and an increase in tumor interstitial fluid pressure. These abnormalities and the microenvironment they create fuel tumor progression and increase the risk of drug resistance. They exert their effects through multiple mechanisms, including the induction of endothelial cell apoptosis, inhibition of endothelial cell migration and proliferation, and the recruitment of new vasculature and invasion of surrounding tissues. The blood supply may also be increased by vascular co-option, vascular intussusception, vasculogenic mimicry, and bone marrow-derived vasculogenesis (Figure 1). Briefly, vascular co-option involves the infiltration of tumor cells into normal tissue and adoption of the pre-existing vasculature. Vessel intussusception is the formation of new vessels by the enlargement and bifurcation of existing vessels. Vasculogenic mimicry is a process in which GB stem-like cells (GSCs) contribute to the formation of tumor blood vessels by differentiating into endothelial cells or pericytes. Bone marrow-derived vasculogenesis involves the recruitment of endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), or hematopoietic stem cells to the tumor, their integration into the vessel wall, and their terminal differentiation into endothelial cells (Figure 1).

The new tumor vasculature is leaky, circuitous, dilated, and saccular, with a haphazard pattern of interconnection. In particular, the endothelial cells lining the new vessels have an irregular, disorganized morphology and are often poorly connected or overlap. The cells supporting the endothelial cells, the pericytes, are loosely attached or absent, and the basement membrane may be abnormally thick or entirely absent. The physiological consequences of these vascular abnormalities include temporal and spatial heterogeneity in tumor blood flow and oxygenation and an increase in tumor interstitial fluid pressure. These abnormalities and the microenvironment they create fuel tumor progression and decrease the efficacy of chemotherapy, radiotherapy, and immunotherapy.12,13

**Antiangiogenic factors and GB**

Given the importance of angiogenesis in GB progression and resistance to treatment, efforts have been made to develop novel therapies based on antiangiogenic factors, to achieve tumor regression through starvation. A number of angiogenesis inhibitors have been shown to affect the growth of various tumors, including GB, and this list is continuing to grow. These inhibitors can be classified into four categories (Figure 2).

**Endogenous antiangiogenic factors**

Endogenous antiangiogenic factors are molecules with antiangiogenic activity naturally present in body fluids or tissues. They are highly attractive candidate drugs because they are relatively non-toxic and well tolerated, with a low risk of drug resistance. They exert their effects through multiple mechanisms, including the induction of endothelial cell apoptosis, inhibition of endothelial cell migration to sites of neovascularization, inhibition of proangiogenic molecules, and changes to the regulation of proangiogenic and antiangiogenic molecules. Some endogenous antiangiogenic factors are secreted by specific cells in different organs. These factors include pigment epithelium-derived factor (PEDF), platelet factor-4 (PF-4), thrombospondin (TSP)-1 and -2, and several members of the interleukin (IL) and interferon (IFN) families, such as IL-4, IL-12, and IFN-β. Others are created by the extracellular proteolytic cleavage of plasma-derived or extracellular matrix proteins, such as angiostatin (fragment of plasminogen), endostatin (fragment of collagen XVIII), PEX (fragment of matrix metalloproteinase-2 [MMP-2]), and vastatin (fragment of collagen VIII). MicroRNAs have also been identified

---

**Figure 2** Antiangiogenic factors and GB.

**Note:** Four categories of angiogenesis inhibitors are used in clinical trials for GB: endogenous factors, monoclonal antibodies, tyrosine kinase inhibitors, and other factors.

**Abbreviations:** GB, glioblastoma; HER2, EGFR-related receptor 2; IFN, interferon; MET, hepatocyte growth factor receptor; PEX, fragment of matrix metalloproteinase-2; PF-4, platelet factor-4; TSP, thrombospondin.
as a new class of endogenous angiogenesis inhibitors. For example, microRNA-16 plays a crucial role in repressing endothelial function and angiogenesis in GB.15 The efficacy of angiostatin, endostatin, PEX, PEDF, and TSP-1 and -2 has been studied in experimental models of malignant gliomas.16,17 However, most of these molecules have not yet been through clinical trials. A Phase I trial was performed to determine the maximum tolerated dose of ABT-510, a TSP-1 mimic drug, used concomitantly with TMZ and radiotherapy in patients with newly diagnosed GB.18 The addition of ABT-510 to TMZ and radiotherapy was well tolerated by patients with GB, without unexpected adverse or serious adverse events. Progression-free and overall survival results were encouraging in light of historical expectations, but no Phase II trial was conducted.

**Antiangiogenic monoclonal antibodies**

Antibodies are key immune system components providing protection against infection. Antibodies directed against proangiogenic signaling proteins have been produced and shown to have antitumor activity in preclinical and clinical trials.19 Bevacizumab (Avastin), a recombinant humanized monoclonal antibody that targets VEGF-A, has been extensively studied in GB. However, Phase III trials showed that although the addition of bevacizumab to the standard treatment for newly diagnosed GB prolonged progression-free survival and improved the performance status of patients, it did not increase overall survival.20,21 Onartuzumab, a humanized monovalent monoclonal antibody against c-Met (or hepatocyte growth factor receptor [HGFR]) was recently evaluated in combination with bevacizumab in patients with recurrent GB.22 This antibody inhibits HGF binding and abolishes the ligand-induced phosphorylation of c-Met. However, no evidence of further clinical benefit was observed in comparisons of onartuzumab plus bevacizumab with bevacinumab plus placebo in unselected patients with recurrent GB.22 Nevertheless, exploratory biomarker analyses have suggested that patients with tumors displaying high levels of HGF or unmethylated O\(^{\text{6}}\)-methylguanine-DNA methyltransferase expression may benefit from treatment with a combination of these two antibodies. Phase I/II trials with three other monoclonal antibodies (cetuximab [anti-epidermal growth factor receptor (EGFR), Erbitux], taniriburam [TTAC-0001, anti-VEGR2], and TRC105 [carotuximab, anti-CD105]) either as single agents or in combination with bevacizumab have either recently been completed or are currently underway in patients with recurrent GB (https://ClinicalTrials.gov).

**Antiangiogenic tyrosine kinase inhibitors (TKIs)**

TKIs have been developed and clinical trials have been performed to assess their ability to block the specific tyrosine phosphorylation (activation) of a panel of angiogenic cell-surface tyrosine kinase receptors, such as VEGFR, bFGFR, platelet-derived growth factor receptor (PDGFR), EGFR, and their downstream intracellular serine/threonine kinases.23 Many of these TKIs are described as “multi-targeted kinase inhibitors” because they target several different kinases. A number of TKIs are being studied in Phase I/II clinical trials in patients with GB24 (Figure 2). To date, limited clinical benefit has been reported following treatment with TKIs in monotherapy or in combination with other approaches for the treatment of GB.24

**Other antiangiogenic factors**

Other antiangiogenic factors have been developed, including VEGF-Trap (afibercept), a soluble VEGF receptor; AMG 386 (trebananib), which binds angiopoietins Ang1 and Ang2; and cilengitide, a potent αvβ3 and αvβ5 integrin antagonist. However, no improvement was observed in patients with GB treated with these factors in clinical trials.25–27

**Effects of antiangiogenic factors on the tumor vasculature**

Antiangiogenic agents are thought to have a direct effect on the tumor vasculature. This effect involves endothelial cell apoptosis and ultimately leads to a cytostatic effect on new blood vessel growth and a decrease in tumor perfusion (Figure 3). These effects restrict the supply of oxygen and nutrients to the tumor, causing “tumor starvation”.7 However, it has also been suggested that antiangiogenic agents achieve their antitumor effects by vascular normalization, decreasing the permeability and diameter of blood vessels, thereby increasing tumor perfusion, decreasing interstitial pressure, and promoting tumor oxygenation (Figure 3). Such conditions sensitize the tumor to radiotherapy and increase the exposure of the tumor to cytotoxic drugs during chemotherapy.28 Antiangiogenic agents may also be active against GSCs29–31 and may disrupt proangiogenic signaling from bone marrow-derived cells, thereby abolishing tumor vascularization.32

**Nonviral delivery methods for antiangiogenic factors**

Many antiangiogenic factors have been discovered, but, like other anticancer drugs, all face challenges to their use in GB therapy. In particular, most antiangiogenic factors
cannot cross the BBB, and do not, therefore, reach therapeutic concentrations in the brain. In GB, the BBB is partially disrupted in the tumor core, but is mostly intact, forming a strong barrier protecting the tumor from the external environment. High systemic levels of antiangiogenic factors are, therefore, required to achieve effective concentrations within the tumor. However, increases in the dose of antiangiogenic agent, or in the frequency and duration of treatment, are often limited by systemic toxicity. For example, the systemic administration of antiangiogenic agents targeting the VEGF pathway has been associated with diverse adverse effects, including cardiovascular and renal complications, hemorrhage, wound complications, gastrointestinal perforation, and reversible posterior leukoencephalopathy syndrome.\(^3^5\) For these reasons, major efforts are currently being made to develop viral and nonviral delivery methods to solve the problem of BBB permeability and to reduce the amounts of antiangiogenic factor required for treatment, thereby decreasing treatment toxicity and adverse effects. We present four main local or systemic nonviral methods for antiangiogenic factor delivery that have been evaluated in orthotopic animal models of GB: convection-enhanced delivery (CED) devices, implantable polymer devices, nanocarriers, and cellular vehicles (Figure 4). The principal results obtained for the use of these devices alone or in combination with chemotherapy or radiotherapy are indicated in Table 1.

### CED devices

In several recent clinical trials on GB, CED has been used for administration of anticancer agents directly into the tumor with a potential to provide concentrations that cannot be achieved with systemic drug delivery.\(^3^4\)\(^-\)\(^3^7\) CED involves the surgical implantation of catheters in the tumor itself or in the surrounding brain parenchyma. The catheters are connected to an infusion pump to create a positive pressure gradient at the catheter tip. This allows for safe, targeted, and reliable homogeneous delivery of small and large molecular weight substances at clinically relevant volumes in a manner that bypasses the BBB. The CED of a mixture of anticancer agent and a surrogate tracer for imaging can now be used to monitor drug distribution in real time by computed tomography or magnetic resonance imaging.\(^3^6\) The preclinical studies performed on animal models in which CED was used to administer angiogenesis inhibitors are listed in Table 1. The CED devices used were based on Alzet osmotic pumps or programmable syringe pumps. Diverse antiangiogenic agents or nanocarriers carrying antiangiogenic factors have been administered in this way...
in GB-bearing animals: bevacizumab, polyplexes (polymer/DNA) encoding a soluble VEGFR-1 (sFlt-1) and an angiostatin-endostatin fusion protein (statin-AE), siRNA targeting hypoxia-inducible factor 1α (HIF-1α), the immuno-toxins, DTAT (diphtheria toxin [DT] targeting urokinase plasminogen activator receptor [uPAR]) and DTATEGF (DT targeting uPAR and EGFR), endostatin or endostatin fused to an antibody (IgG) Fc domain (Fc-endostatin), two mechanistically different inhibitors of the CYP/CYP450 2C11 epoxygenase, 17-octadecynoic acid and miconazole, and sorafenib-loaded lipid nanocapsules (SFN-LNCs). The administration of these agents by CED has frequently been shown to lead to a significant decrease in capillary formation and tumor size and an increase in animal survival. Wang et al demonstrated that bevacizumab administered by CED resulted in longer animal survival than the same drug administered intravenously. Furthermore, combining the CED of angiogenesis inhibitors (bevacizumab or Fc-endostatin) with the systemic administration of chemotherapy agents (CPT-11 or TMZ) was found to be the most effective approach for increasing survival. One clinical trial of intracerebral infusion by CED was performed with a recombinant toxin, TP-38, targeting the EGFR in patients with recurrent GB. The CED of TP-38 was found to be well tolerated at effective doses and encouraging radiographic responses were observed. However, this trial also showed that the potential efficacy of agents delivered by CED in humans might be limited by inconsistent and inefficient infusion in many patients. These technical shortcomings will need to be addressed if CED is to fulfill its therapeutic potential.

### Implantable polymer devices
Implantable polymer devices provide a robust technology platform for the local and sustained delivery of drugs directly to the tumor. Gliadel wafers are currently the only biodegradable polymer implants for intracranial drug delivery approved for GB treatment by the US Food and Drug Administration (FDA) and the European Medicines Agency.
Table 1 Nonviral antiangiogenic factor delivery methods evaluated in orthotopic GB animal models

| Delivery method | Antiangiogenic factor | Administration | GB model | Major results                                                                                                                                                                                                 | Reference |
|-----------------|-----------------------|----------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| CED devices     |                       |                |          |                                                                                                                                                                                                              |           |
| Osmotic pump    | Avastin (bevacizumab) | IT or IV       | Human U87MG/ U251 | U251 tumor-bearing mice treated with CED of bevacizumab alone or in combination with CPT-11 survived longer than those treated systemically: U251 tumor alone: 23 days [CPT-11] 24 days [Avastin_IV] 26 days [Avastin_CED] 36 days [Avastin_IV + CPT-11] 33 days [Avastin_CED + CPT-11] 37 days A similar effect was obtained with the U87MG model | 38        |
| Programmable syringe pump | Polypelexes: (sFt-1/statin-AE/PEI) | IT | Human U87-Luc | CED of sFt-1/statin-AE/PEI polypelexes caused complete tumor regression: 18% of animals were tumor-free                                                                                                       | 39        |
| Osmotic pump    | siRNA targeting HIF-1α/PEG | IT | Human U87-Luc | CED of siRNA targeting HIF-1α enhanced survival: [Control PEG-siRNA] 18 days [PEG-siRNA1589] 35 days                                                                                                             | 40        |
| Osmotic pump    | Immunotoxins: DTAT/DTATEGF | IT | Human U87-Luc | CED of DTAT or DTATEGF inhibited the growth of U87-Luc GB cells in nude mice and killed small solid tumors                                                                                                 | 41        |
| Osmotic pump    | Endostatin            | IT | Human U87MG | CED of endostatin enhanced survival: [U87MG tumor alone] 26 days [Endostatin] 34 days                                                                                                                           | 43        |
| Programmable syringe pump | Fc-endostatin [± TMZ (O)] | IT | Rat 9L | CED of Fc-endostatin enhanced survival, with an even greater increase when Fc-endostatin was combined with TMZ: [9L tumor alone] 13 days [TMZ] 21 days [Fc-endostatin] 14 days [Fc-endostatin + TMZ] 23 days | 42        |
| Osmotic pump    | Inhibitors of CYP epoxygenase: 17-ODYA or miconazole | IT | Rat RG2 | CED of inhibitors of CYP epoxygenase enhanced survival: [RG2 tumor alone] 17 days [17-ODYA] 22 days [Miconazole] 23 days                                                                                       | 44        |
| Programmable syringe pump | SFN-LNCs             | IT | Human U87MG | CED of SFN-LNCs decreased the proportion of proliferating cells in the tumor and induced early tumor vascular normalization, characterized by increases in tumor blood flow and decreases in tumor vessel area | 45        |
| Two barium-impregnated catheters | TP-38               | IT | Phase I trial on recurrent GB | CED of TP-38 was well tolerated and produced some durable radiographic responses at doses <100 ng/mL                                                   | 46        |
| Implantable polymer devices |                       |                |          |                                                                                                                                                                                                              |           |
| EVAc disk       | Minocycline [± BCNU (IP)] | IT | Rat 9L | Minocycline polymer implantation combined with BCNU enhanced survival relative to BCNU alone: [9L tumor alone] 13 days [Minocycline polymer] 13 days [BCNU] 28 days [Minocycline polymer + BCNU] 55 days | 57        |
| CPP-SA wafer    | Minocycline [± BCNU (IP)] | IT | Rat 9L | Minocycline polymer implantation enhanced survival, with even greater effects when minocycline was combined with BCNU: [9L tumor alone] 14 days                                                                 | 56        |

(Continued)
| Delivery method                  | Antiangiogenic factor | Administration | GB model       | Major results                                                                                                                                                                                                 | Reference |
|---------------------------------|-----------------------|----------------|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| CPP-SA wafer                    | Minocycline [± TMZ (O) or RT] | IT             | Rat 9L         | Minocycline delivered locally potentiated the effects of both radiotherapy and oral TMZ, increasing median survival in 9L tumor-bearing rats: [9L tumor alone]: 14 days [TMZ]: 21 days [RT]: 31 days; 6.7% long-term survivors [Minocycline polymer]: 19 days [Minocycline polymer + TMZ]: 29 days; 6.3% long-term survivors [Minocycline polymer + RT]: 74 days; 46.7% long-term survivors | 55        |
| CPP-SA wafer                    | Fc-endostatin [± TMZ (O)] | IT             | Rat 9L         | Fc-endostatin polymer implantation enhanced survival; which was increased still further by the combination of Fc-endostatin with TMZ: [9L tumor alone]: 13 days [TMZ]: 21 days [Fc-endostatin polymer]: 15 days [Fc-endostatin polymer + TMZ]: 28 days | 42        |
| PLGA nanofibrous membrane       | PTX/siRNA targeting MMP-2 | IT             | Human U87MG-Luc2 | The PTX/siRNA dual implant significantly enhanced tumor growth inhibition, by a factor of about 30 relative to PTX implant only                                                                                     | 63        |
| PLGA nanofibrous membrane       | BIC + combretastatin (BICC) | IT             | Rat C6         | BICC/PLGA nanofibrous membrane implantation enhanced survival: [C6 tumor alone]: 23 days [BIC/PLGA]: 60 days [BICC/PLGA]: 87 days                                                                                      | 64        |
| PLGA microspheres               | PF-4/CTF               | IT             | Human U87MG     | A single injection of microspheres containing PF-4/CTF caused a 65% reduction in tumor volume relative to empty microspheres                                                                                       | 65        |
| Nanocarriers                    |                        |                |                |                                                                                                                                                                                                             |           |
| Polypexes                       | sFlt-1/statin-AE/PeI   | IT             | Human U87-Luc  | CED of sFlt-1/statin-AE/PEI polypelexes caused complete tumor regression: 18% of animals were tumor-free                                                                                                        | 39        |
| Polypexes                       | IL-12/PPC [± BCNU wafer] | IT             | Mouse GL261    | Local delivery of IL-12/PPC polypelexes enhanced survival, which was increased still further by combining pmIL-12/PPC with BCNU: [GL261 tumor alone]: 45 days [IL-12/PPC]: 57 days; 25% long-term survivors [BCNU]: 75% long-term survival [IL-12/PPC + BCNU]: 100% long-term survivors | 76        |
| Polypexes                       | Vastatin or endostatin/folate-PEI600-CyD (H1) [± TMZ (IP)] | IT             | Human U87MG/U87MG-ATR | Local delivery of vastatin or endostatin/H1 enhanced survival of U87MG tumor-bearing mice: [U87MG tumor alone]: 48 days [Control DNA/H1]: 51 days [Vastatin/H1]: 75 days [Endostatin/H1]: 64 days Local delivery of vastatin/H1 synergized with TMZ and restored the sensitivity of chemoresistant U87MG-ATR-bearing mice to TMZ treatments: [U87-ATR tumor alone]: 25 days [Control DNA/H1]: 23 days | 75        |

(Continued)
Table 1 (Continued)

| Delivery method | Antiangiogenic factor | Administration | GB model | Major results | Reference |
|-----------------|----------------------|----------------|----------|---------------|-----------|
|                 | [TMZ]: 29 days       |                |          |               |           |
|                 | [Vastatin/H1]: 34 days|                |          |               |           |
|                 | [Vastatin/H1 + TMZ]: 54 days |        |          |               |           |
| LNCs            | SFN                  | IT             | Human U87MG | CED of SFN-LNCs decreased the proportion of proliferating cells in the tumor and induced early tumor vascular normalization, characterized by increases in tumor blood flow and decreases in tumor vessel area | 45 |
| **Cellular vehicles** |                      |                |          |               |           |
| **Microencapsulated cells** |                      |                |          |               |           |
| Human fetal kidney 293 cells/alginate microcapsules | Endostatin | IT | Rat BT4C | Mice orthotopically implanted with a mixture of tumor cells and endostatin bioreactors displayed enhanced survival: [BT4C tumor alone]: 22 days [Endostatin bioreactors]: 40 days; 30% long-term survivors | 82 |
| Human fetal kidney 293 cells/alginate microcapsules | Endostatin | IT | Rat C6 | Endostatin bioreactors inhibited tumor cell invasion and reduced the functionality and diameters of the tumor-associated microvessels | 83, 84 |
| **Adult stem cells** |                      |                |          |               |           |
| **NSCs** |                      |                |          |               |           |
| Mouse NSCs      | IL-12                | IT             | Mouse GL26 | Intratumoral injection of IL-12-producing NSCs prolonged survival and induced long-term immunity. [GL26 tumor alone]: 35 days [NSC-Control]: 35 days [NSC-IL-12]: 49 days; 30% long-term survivors | 88 |
| Human NSCs      | IL-12                | IT             | Rat C6 | Intratumoral injection with IL-12-secreting NSCs prolonged survival: [C6 tumor alone]: 17 days [NSC-IL-12]: 73 days; 50% long-term survivors | 93 |
| Human NSCs      | TSP-1                | IT             | Human Gli36-EGFRvIII-FD | Intratumoral injection of TSP-1-producing NSCs prolonged survival: [NSC-Control]: 23 days [NSC-IL-12]: 29 days | 92 |
| Mouse NSCs      | Endostatin           | IT             | Mouse GL261 | Intratumoral injection of endostatin-producing NSCs caused a 65% reduction in tumor size relative to the injection of control NSCs | 90 |
| Human NSCs      | PEX                  | IT             | Human U87MG | Intratumoral injection of PEX-producing NSCs caused a 82% reduction in tumor size relative to the injection of control NSCs | 89 |
| **MSCs** |                      |                |          |               |           |
| Human MSCs      | [Endostatin ± sCE2 [± CPT-11 (IV)]] | IT         | Human U87MG-EGFRvIII | Delivery of endostatin and sCE2 by MSCs at the tumor sites, along with CPT-11 treatment, resulted in reliable antitumor effects in U87MG-EGFRvIII-driven orthotopic brain tumor and postsurgery tumor recurrence models | 94 |
| Human MSCs      | TSP-1 (3TSR) ± sTRAIL | IT           | Human LN229-Fluc-mCherry | Intratumoral injection of 3TSR/sTRAIL-producing MSCs prolonged survival: [MSC-Control]: 38 days [MSC-3TSR]: 45 days [MSC-sTRAIL]: 55 days [MSC-3TSR/sTRAIL]: 68 days | 86 |

(Continued)
Two intranasal administrations of SFN-primed MSCs
IL-12
IT
Rat 9L
IN
IT
Human U87MG
Reference
IFN-α
53
Intratumoral injection of IL-12-producing MSCs
2506
median survival of treated rats
25
54
agents (BCNU or TMZ) or radiotherapy, increasing the
clinic wafer potentiated the effects of systemic chemotherapy
DIS
53
 economical angiogenesis inhibitor, has also been loaded onto
the oral chemotherapy agent TMZ
25
54
Fc-endostatin via CPP-SA wafers or CED was combined with
benefits were observed when the intratumoral delivery of
rats.
25
52
intraperitoneal; IT, intratumoral; LNCs, lipid nanocapsules; Luc, luciferase; MMP-2, matrix metalloproteinase-2; MSCs, menenchymal stromal cells; NSCs, neural stem cells; O, oral; 17-ODYA, 17-octadecynoic acid; PEG, polyethylene glycol; PEI, polyethylenimine; PEX, fragment of MMP-2; PF-4/CTF, C-terminal fragment of platelet factor-4; PLGA, poly(D,L-lactide-co-glycolide); PPC, PEI covalently linked to methoxy-polyethyleneglycol and cholesterol functional groups; PTX, paclitaxel; RT, radiotherapy; sCE2, secretable form of carboxylesterase 2; sFlt-1, soluble VEGFR-1; siRNA, small interfering RNA; SA, sebacic acid; SFN, sorafenib; Statin-αE, angostatin-endostatin fusion protein; TMZ, temozolomide; TP-38, recombinant toxin targeting eGFR; sTRAIL, secretable variant of tumor necrosis factor-related apoptosis-inducing ligand 1; TSP-1, thrombospondin-1; 3TSR, three type-1 repeat domain of TSP-1.
(EMA).49–51 They are made of a polyanhydride copolymer
1,3-bis[2-chloroethyl]-1-nitrosourea [BCNU]. Gliadel wafers are implanted in the
tumor bed after resection. They provide a controlled local
release of BCNU over a period of 2–4 weeks. This delivery
system was shown to be superior to the systemic administration
of BCNU in the 9L rat glioma model, and its systemic
toxicity was limited.52 Clinical studies have reported Gliadel
wafers to be effective against both newly diagnosed and
recurrent GB.53 The combination of Gliadel wafers with standard radiotherapy plus concurrent and adjuvant TMZ
has been shown to increase patient survival by 3–4 months
relative to Gliadel wafers or TMZ alone.54 The antiangiogenic agent Fe-endostatin has been loaded onto CPP-SA
wafers, and the intracranial implantation of Fe-endostatin
wafers was found to prolong survival in 9L tumor-bearing
rats.42 A similar effect on survival has been reported for
the CED of Fe-endostatin to the tumor.42 Additional survival
benefits were observed when the intratumoral delivery of
Fe-endostatin via CPP-SA wafers or CED was combined with
the oral chemotherapy agent TMZ42 (Table 1). Minocycline,
another angiogenesis inhibitor, has also been loaded onto
CPP-SA wafers, and the intracranial implantation of minocy-
cline wafers potentiated the effects of systemic chemotherapy
agents (BCNU or TMZ) or radiotherapy, increasing the
median survival of treated rats55,56 (Table 1). Weingart et al57
incorporated minocycline into ethylene-vinyl acetate copo-
lymer (EVAc), a non-biodegradable polymer. They found
that a combination of the local delivery of minocycline from
EVAc disks and systemic BCNU increased median survival
by 93% relative to BCNU alone in 9L tumor-bearing rats.
Other studies have used poly[(D,L)-lactide-co-glycolide] (PLGA) nanofibrous membranes to deliver antiangiogenic
factors. PLGA, an FDA- and EMA-approved polymer, is
highly biocompatible and biodegradable, and is one of the
most attractive polymeric candidates available for the manu-
facture of devices for drug-delivery and tissue-engineering
applications.58,59 PLGA nanofibrous membranes are thinner
than Gliadel wafers, can be cut into any size or shape, and
can conform completely to the shape of the tissue after tumor
removal.60 Various drugs can be incorporated into these mem-
bones easily, and the use of PLGA nanofibrous membranes
with different lactic acid/glycolic acid compositions can yield
different PLGA degradation profiles, making it possible to
control the sequential elution of drugs and their release at ther-
apedic doses.61,62 PLGA nanofibrous membranes also provide
a longer therapeutic period (more than 8 weeks) than Gliadel
wafers (2–4 weeks), potentially resulting in a higher ther-
apetic efficacy and lower resistance. Lei et al63 incorporated
paclitaxel (PTX) and polyplexes encoding a siRNA targeting
MMP-2 into PLGA nanofibrous membranes. MMP-2 is an
essential proteinase regulating brain tumor invasion and
angiogenesis. This dual delivery of PTX and MMP-2 siRNA

### Table 1 (Continued)

| Delivery method | Antiangiogenic factor | Administration | GB model | Major results | Reference |
|-----------------|-----------------------|----------------|----------|---------------|-----------|
| Human MSCs      | IL-12                 | IT             | Mouse GL26 | Intratumoral injection of IL-12-producing MSCs prolonged survival: [GL26 tumor alone]: 46 days [MSC-Control]: 51 days [MSC-IL-12]: 70% long-term survivors | 91        |
| Rat MSCs        | IFN-α                 | IT             | Rat 9L    | Rats implanted with a mixture of tumor cells and IFN-α-producing MSCs displayed enhanced survival: [MSC-Control]: 16.5 days [MSC-IFN-α]: 19 days | 87        |
| Human MSCs      | SFN                   | IN             | Human U87MG | Two intranasal administrations of SFN-primed MSCs in U87MG tumor-bearing mice resulted in lower levels of tumor angiogenesis than the injection of unprimed MSCs or SFN alone but had no effect on tumor volume | 96        |

**Abbreviations:** ATR, acquired TMZ resistance; BCNU, 1,3-bis[2-chloroethyl]-1-nitrosourea; BIC, BCNU-irinotecan-cisplatin; BICC, BIC-combretastatin; CED, convection-enhanced delivery; CPP, 1,3-bis[p-carboxyphenoxy] propane; CPT-11, Camptosar (irinotecan); CYP epoxygenase, cytochrome P450 2C11 epoxygenase; DTAT, diphtheria toxin (DT) targeting urokinase plasminogen activator receptor (uPAR); DTATeGF, DT targeting uPAR and eGFR; EVAc, ethylene-vinyl acetate copolymer; Fe-endostatin, recombinant human endostatin conjugated to the Fc domain of IgG; FD, Fluc-DsRed2; GB, glioblastoma; HIF, hypoxia-inducible factor; IFN, interferon; IL, interleukin; IP, intraperitoneal; IT, intratumoral; LNCs, lipid nanocapsules; Luc, luciferase; MMP-2, matrix metalloproteinase-2; MSCs, mesenchymal stromal cells; NSCs, neural stem cells; O, oral; 17-ODYA, 17-octadecynoic acid; PEG, polyethylene glycol; PEI, polyethylenimine; PEX, fragment of MMP-2; PF-4/CTF, C-terminal fragment of platelet factor-4; PLGA, poly(D,L-lactide-co-glycolide); PPC, PEI covalently linked to methoxy-polyethyleneglycol and cholesterol functional groups; PTX, paclitaxel; RT, radiotherapy; sCe2, secretable form of carboxylesterase 2; sFlt-1, soluble VEGFR-1; siRNA, small interfering RNA; SA, sebacic acid; SFN, sorafenib; Statin-αE, angostatin-endostatin fusion protein; TMZ, temozolomide; TP-38, recombinant toxin targeting eGFR; sTRAIL, secretable variant of tumor necrosis factor-related apoptosis-inducing ligand 1; TSP-1, thrombospondin-1; 3TSR, three type-1 repeat domain of TSP-1.
by PLGA nanofibrous membranes was tested in mice with intracranial U87MG-Luc2 xenografts, and was found to have a significantly greater therapeutic efficacy than the delivery of PTX alone, with the two agents acting in synergy. Tseng et al,64 loaded 50:50 PLGA nanofibers with three chemotherapy agents (BCNU, irinotecan, and cisplatin; BIC/PLGA), and 75:25 PLGA nanofibers with BIC and an antiangiogenic agent (combretastatin phosphate, CA4P; BICC/PLGA). The chemotherapy agents were rapidly released from the 50:50 PLGA nanofibers after implantation, and combretastatin was released from the 75:25 PLGA nanofibers about 2 weeks later. BICC/PLGA nanofibrous membranes implanted in the brains of C6 tumor-bearing rats slowed tumor growth and decreased malignancy more effectively than BIC/PLGA nanofibrous membranes.

One study used PLGA microspheres to deliver an antiangiogenic factor, C-terminal fragment of PF-4 (PF-4/CTF).65 This study showed that the intratumoral injection of PF-4/CTF-loaded microspheres in U87MG tumor-bearing mice decreased tumor volume by about 70%, this effect being accompanied by a significant decrease in angiogenesis and an increase in apoptosis. Microspheres constitute a versatile class of drug carriers for which drug release kinetics can be controlled by modulating microsphere formulation (size, molecular weight, and PLGA composition).66 Due to their size and shape, polymeric microspheres are easy to implant at the tumor site by stereotactic injection, or to inject into the walls of brain tumor resection cavities with a handheld syringe during surgery.67

Encouraging results have been obtained with implantable polymer devices, but further optimization of these devices is required to overcome the specific challenges of localized treatment, including sustainable release over a long period and deeper tissue penetration.68 Polymeric microreservoirs could potentially improve the efficacy of local treatment for brain cancer, as they can deliver large doses of drugs in solid or liquid form. For example, Ong et al developed a microdevice consisting of a micromachined polysulfone reservoir and cap. The reservoir was drug-impermeable and consisted of a cylinder of 2 mm in diameter and 2 mm in height. The cap of the device was machined with pores of 300 μm in diameter through which the encapsulated drug could pass. Drug release from this polysulfone microdevice was linear and highly dependent on the number of holes in the cap: the greater the number of holes, the faster the release of the drug. Grayson et al produced another form of microreservoir consisting of a polymeric microchip device. These microchips were 1.2 cm in diameter and 480–560 μm thick, and they had 36 reservoirs, each of which could be loaded with a different substance. These devices were made of polylactic acid (PLLA) and each reservoir was covered with a PLGA membrane. By altering the molecular mass of the PLGA membrane, drug delivery systems could be developed with the potential to release pulses of different drugs at different times after implantation in a patient.

Nanocarriers

The use of nanocarriers for cancer treatment has been described in a number of studies.31–74 Nanocarriers are particles with at least one dimension in the 1–1,000 nm size range. They can be used for the local or systemic delivery of various agents, such as drugs, radionuclides, imaging agents, and bioactive compounds (siRNA or DNA). These agents can be entrapped in, adsorbed onto, or chemically bonded to the nanocarrier surface. Nanocarriers protect the active agents against enzymatic and hydrolytic degradation, improve their solubility and pharmacokinetic parameters, and control their release. Their composition, size, and other surface characteristics can easily be modified to bypass physiological barriers, including the BBB. Various nanocarriers are available: polymeric, lipid-based, and inorganic.

Two types of nanocarriers have been developed for antiangiogenic therapy: 1) nanocarriers carrying antiangiogenic factors, and 2) vascular-targeted nanocarriers generated by the conjugation of nanocarriers to molecules that bind to angiogenesis-related receptors. These nanocarriers can be used to detect and visualize angiogenesis and/or to direct chemotherapy, phototherapy, or gene therapy to the tumor vasculature. In this review, we present only the nanocarriers used for antiangiogenic factor delivery.

An entire arsenal of nanocarriers carrying antiangiogenic factors has been produced, but few have been tested in orthotopic GB models. We identified three studies reporting the use of polyplexes for the delivery of genes encoding antiangiogenic factors in addition to the work of our laboratory on the use of LNCs for SFN delivery (Table 1; Figure 4). Ohlfest et al produced polyplexes encoding two antiangiogenic proteins, sFlt-1 and statin-AE. They showed that the CED of these polyplexes in U87MG tumor-bearing mice led to strong antitumor activity characterized by a decrease in tumor vessel density, the inhibition of tumor growth, and tumor elimination in up to 50% of mice (Table 1). In other studies, polyplexes encoding IL-12 and vastatin or endostatin were produced.75,76 The intratumoral injection of these antiangiogenic polyplexes in GB-bearing mice led to a significant increase in survival relative to untreated mice, which was increased still further by their combination with chemotherapy agents (BCNU or TMZ) (Table 1).
Our laboratory recently produced LNCs for SFN encapsulation, because this multikinase inhibitor is poorly soluble in water, which limits its use for local or systemic administration.43 We showed that the CED of SFN-LNCs in the orthotopic U87MG GB model decreased the proportion of proliferating cells in the tumor and induced early tumor vascular normalization, characterized by an increase in tumor blood flow and a decrease in tumor vessel area (Table 1). This vascular normalization may provide a window of opportunity for enhancing the efficacy of chemotherapy or radiotherapy.

Cellular vehicles
Cellular vehicles, including microencapsulated cells and adult stem cells, have been used to deliver antiangiogenic factors in orthotopic GB models (Table 1; Figure 4).

Microencapsulated cells
Living cells are encapsulated in polymeric microspheres or microcapsules for many biomedical and biotechnological applications, including local and long-term drug delivery and regenerative medicine.77-81 The microencapsulation of cells allows the free exchange of nutrients and waste while excluding agents of the immune system, thereby promoting the survival of the implanted cells. It also permits the release of therapeutic cell products. A number of different biomaterials, such as alginate, hyaluronic acid, agarose, and other polymers, have been used for encapsulation.

Read et al82 encapsulated human fetal kidney 293 cells transfected with a pCEPPu episomal expression vector encoding human endostatin in sodium alginate microcapsules. They showed that encapsulated endostatin-producing 293 cells remained viable for at least 4 months after intracerebral implantation, and that they continued to produce endostatin after encapsulation and implantation. The spatial distribution of endostatin in the brain/tumor tissue was determined, and this molecule was detected at 1–1.7 mm from the bioreactors, with some more distant deposits (4–6 mm). It was also found in the cerebrospinal fluid. Rats receiving transplants of BT4C glioma cells together with encapsulated endostatin-producing 293 cells survived for 84% longer than controls. The endostatin released from the microcapsules triggered apoptosis, hypoxia, and the formation of large necrotic avascular areas in 77% of the treated tumors, whereas these features were not observed in any of the controls. The apparent biological effects of endostatin were observed for tumors inoculated 1 week before or at the same time as bioreactor implantation. However, no significant effect on animal survival was observed when animals received the treatment 1 week after tumor inoculation.

Intravital multifluorescence microscopy showed that the endostatin released from the capsules decreased not only total vascular density, but also the functionality and diameter of blood vessels and tumor cell invasion.83,84 Efforts are currently being made to encapsulate cell lines producing different recombinant proteins capable of interfering with tumor growth and progression. In this way, a “library” of encapsulated cells can be generated, with the aim of tailoring local therapy to specific biological parameters regulating tumor growth. In parallel, optimization is required to achieve sufficient biosafety and biocompatibility for clinical approval.

Adult stem cells
The particular tropism for brain tumors displayed by stem cells, such as neural stem cells (NSCs) and MSCs, has led these cells to being considered potential candidate treatment delivery agents.83 Adult NSCs are found within the subventricular zone and the hippocampal dentate gyri and give rise to neurons and glia. The preparation of sufficient numbers of autologous NSCs for clinical applications remains technically challenging. Fetal brain, adult allogeneic brain, and embryonic stem cells are therefore all currently being considered as possible substitutes for autologous NSCs. MSCs are multipotent cells capable of differentiating into multiple cell types, including chondrocytes, adipocytes, and osteoblasts. They were originally isolated from bone marrow, but can be obtained from many other sources, including peripheral blood, umbilical cord blood, and adipose tissue. MSCs are an attractive alternative to NSCs because they are easy to propagate in vitro and because the implantation of autologous MSCs in patients with GB entails fewer ethical problems. In most studies of antiangiogenic therapy with NSCs or MSCs, these cells are genetically modified to express IL-12, endostatin, IFN-α, TSP-1, or PEX and are delivered directly to the brain tumor.86-94 The treatment of intracranial gliomas with these engineered cells has been shown to inhibit tumor progression, and/or to increase survival in mice (Table 1). Furthermore, the simultaneous delivery of antiangiogenic factors (endostatin or TSP-1) and chemotherapy factors (a secretable form of carboxylesterase 2 [sCE2] along with CPT-11 treatment or a secretable variant of tumor necrosis factor-related apoptosis-inducing ligand [TRAIL]) by MSCs yielded the stronger antitumor responses86,94 (Table 1). We recently showed that MSCs can deliver the chemotherapy drug ferrociphenol and the antiangiogenic TKI SFN to brain tumors without the need for genetic modification.95,96 MSCs can be primed in vitro with SFN, with no effect on viability, and can release 60% of the drug with which they
are conserved. The antiangiogenic activity of the released SFN was entirely conserved, significantly decreasing the survival of human U87MG GB cells and endothelial cells in vitro. We investigated the in vivo effect of SFN-primed MSCs on the orthotopic U87MG GB model, following their intranasal administration. Unlike direct intracranial delivery, intranasal delivery is noninvasive, making the repeated administration of treatment possible. Furthermore, this delivery route appears to be a promising alternative to intravenous injections of MSCs, which generally lead to the entrapment and elimination of MSCs in peripheral organs and a risk of vascular and pulmonary embolization. The treatment of U87MG tumor-bearing mice with two intranasal administrations of SFN-primed MSCs 4 days apart has been shown to result in lower levels of tumor angiogenesis than the injection of unprimed MSCs or SFN alone, but with no effect on tumor volume. The absence of an effect on tumor volume is probably due to the use of too low a dose of SFN-primed MSCs. The intranasal administration of larger numbers of SFN-primed MSCs may be required for an effect on U87MG growth. No clinical trial has yet been performed to assess the use of MSCs as cellular vehicles for GB therapy. One reason for this may be the widespread use of viral vectors for the production of therapeutic MSCs. The use of viruses is associated with a number of disadvantages, including risks of toxicity, immunogenicity, insertional mutagenesis, and high manufacturing costs. Another possible reason is the conflicting data published concerning the use of MSCs in cell-based therapies. The role of MSCs in cancer progression remains a matter of heated debate, but the number of studies reporting a role for these cells in cancer progression is steadily increasing. Consistent with the findings of these studies, we found that the intranasal administration of unprimed MSCs induced a significant increase in the number of small vessels in the U87MG tumor, which was abolished when MSCs were primed with SFN. Several studies have indicated that MSCs promote angiogenesis by secreting angiogenic factors, such as VEGF, releasing exosomes, recruiting endothelial progenitors, and/or transdifferentiating into endothelial cells. Our previous studies showed no effect of unprimed MSCs on tumor volume or the proportion of Ki67 tumor cells in the human U87MG GB model, but MSCs have been reported to facilitate tumor growth by secreting various anti-inflammatory cytokines and proangiogenic factors. Furthermore, MSCs can differentiate into cancer-associated fibroblasts (CAFs), which have been detected in the stroma of carcinomas and are known to promote tumor growth. In the GB peritumoral environment, we identified MSC-like cells that

### Conclusion

Various nonviral delivery methods, including CED devices, implantable polymer devices, nanocarriers, and cellular vehicles, have been developed to improve the efficacy of GB treatment with antiangiogenic factors. All these delivery methods, tested in orthotopic GB models, were found to be effective, but only CED devices have been translated into clinical practice. Studies showing clear-cut advantages of one particular type of antiangiogenic factor delivery method over another in a representative GB model would facilitate the translation of such methods from the bench to the clinic (Figure 5). For such studies, there is an urgent need to identify the angiogenesis inhibitors giving the best response in preclinical studies and to focus on cheap, easily produced biocompatible nonviral delivery methods that could be rapidly transferred into clinical practice. The delivery route is also a major matter of concern that must be addressed. CED devices, implantable polymer devices, and microencapsulated cells are local delivery methods. They have the advantage of providing higher concentrations of antiangiogenic factors in the tumor than systemic delivery methods. However, they require intracranial surgery, which is not compatible with the use of factors for which
a regime involving repeated injections is required for an effect on the tumor vasculature. In this case, nanocarriers or adult stem cells, which can be administered systemically, should be favored. Furthermore, it should also be borne in mind that angiogenesis inhibitor therapy alone is not sufficient to counteract the growth of GB, given the aggressiveness of this type of brain cancer and its resistance to various treatments. Further studies will therefore also be required to evaluate and optimize dosing schedules, for the development of effective combinations of the selected antiangiogenic factor delivery method with other treatments, such as chemotherapy, radiotherapy, and phototherapy. All these studies will take time but are necessary to ensure that the selected antiangiogenic factor delivery method is of unequivocal and meaningful clinical benefit to GB patients in the future. Particular attention should be paid to the emerging vascular-targeted nanotheranostic devices consisting of multifunctional nanocarriers for both diagnosis and the delivery of therapeutic agents to the tumor vasculature.122

The results obtained with these systems in preclinical models of GB should be monitored to determine whether they are likely to be more effective than antiangiogenic factor delivery methods (Figure 5).

**Acknowledgments**

This work was supported by grants from the “Fondation de France”, “Ligue Contre le Cancer du Grand-Ouest, Comité Départemental du Maine-et-Loire”, “Association en Avant la Vie”, and the European Commission, Education, Audiovisual and Culture Executive Agency (EACEA), through the NanoFar Erasmus Mundus joint Doctoral program. We thank Professor Franck Boury (Team 17, GLIAD, CRCINA, INSERM 1232, Angers), Doctor Snow Stolnik, and Doctor Cynthia Bosquillon (School of Pharmacy, University of Nottingham, Nottingham, UK) for providing facilities. We also thank Alex Edelman and associates for correcting the manuscript.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.

2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
3. de Groot J, da R, Batchelor TT. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. *Am Soc Clin Oncol Educ Book*. 2013. doi:10.1200/EdBook_AM.2013.33.e71.

4. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. *J Clin Oncol Off J Am Soc Clin Oncol*. 2013;31(26):3212–3218.

5. Khosrav A, Ameratunga M, Grommes C. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. *Expert Opin Biol Ther*. 2014;14(5):729–740.

6. Lenting K, Verhaak R, Ter Laan M, Wesseling P, Leenders W. Glioma: experimental models and reality. *Acta Neuroanatologica*. 2017;133(2):263–282.

7. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med*. 1971;285(21):1182–1186.

8. Das S, Marsden PA. Angiogenesis in glioblastoma. *N Engl J Med*. 2013;369(16):1561–1563.

9. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. *Am J Pathol*. 2012;181(4):1126–1141.

10. Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and antiangiogenic therapy in malignant gliomas revisited. *Acta Neuropathologica*. 2012;124(6):763–775.

11. Wang N, Jain RK, Batchelor TT. New directions in anti-angiogenic therapy for glioblastoma. *Neurotherapeutics*. 2017;14(2):321–332.

12. Dimberg A. The glioblastoma vasculature as a target for cancer therapy. *Biochim Soc Trans*. 2014;42(6):1647–1652.

13. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. *Nat Rev Neurosci*. 2007;8(8):610–622.

14. Rao N, Lee YF, Ge R. Novel endogenous angiogenesis inhibitors and their therapeutic potential. *Acta Pharmacol Sin*. 2015;36(10):1177–1190.

15. Chen F, Chen L, He H, et al. Up-regulation of microRNA-16 in glioblas
toma inhibits the function of endothelial cells and tumor angiogenesis by targeting Bmi-1. *ACAMC*. 2016;16(5):609–620.

16. Gagnon-J, Law M, Fischer I, Newcomb EW, Zagzag D. Angiogenesis in gliomas: imaging and experimental therapeutics. *Brain Pathology*. 2005;15(4):342–363.

17. Rege TA, Fears CY, Gladson CL. Endogenous inhibitors of angiogenesis in malignant gliomas: nature’s antiangiogenic therapy. *Neuro-Oncol*. 2005;7(2):106–121.

18. Nabors LB, Fievez JB, Markert JM, et al. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. *Arch Neurol*. 2010;67(3):313–319.

19. Kong D-H, Kim MR, Jang JH, Na H-J, Lee S. A review of antiangiogenic targets for monoclonal antibody cancer therapy. *Brain Pathology*. 2005;15(4):342–363.

20. Chirot OL, Reardon DA. The future of antiangiogenic treatment in glioblastoma. *Current Opinion in Neurology*. 2014;27(6):675–682.

21. Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370(21):2048–2049.

22. Cloughey T, Finocchiaro G, Belda-Iniesta C, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hematocyte growth factor and O*-methylguanine–DNA methyltransferase biomarker analyses. *J Clin Oncol Off J Am Soc Clin Oncol*. 2017;35(3):343–351.

23. Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? *Angiogenesis*. 2010;13(1):1–14.

24. Popescu AM, Purcaru SO, Alexandria O, Drincu A. New perspectives in glioblastoma antiangiogenic therapy. *Wspoleczna Onkologia*. 2016;2(2):109–118.

25. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American brain tumor Consortium study. *J Clin Oncol Off J Am Soc Clin Oncol*. 2011;29(19):2689–2695.

26. Reardon DA, Lassman AB, Schiff D, et al. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptide, with and without bevacizumab for patients with recurrent glioblastoma. *Cancer*. 2018;124(7):1438–1448.

27. Weller M, Nabors LB, Gorlia T, et al. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. *Oncotarget*. 2016;7(12):15018–15032.

28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science*. 2005;307(5706):58–62.

29. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. *Cancer Cell*. 2007;11(1):69–82.

30. Cheng L, Huang Z, Zhou W, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. *Cell*. 2013;153(1):139–152.

31. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. *Cancer Res*. 2007;67(8):3560–3564.

32. de Groot JF, Piao Y, Tran H, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. *Clinical Cancer Research*. 2011;17(14):4872–4881.

33. Chen HX, Cleeck JN. Adverse effects of anticancer agents that target the VEGF pathway. *Nat Rev Oncol*. 2009;8(8):465–477.

34. Jahanpir A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, Aghi MK. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. *J Neurosurg*. 2017;269(3):191–200.

35. Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. *Neurotherapeutics*. 2017;14(2):358–371.

36. Nedsen VMO. Convection-enhanced delivery of neurotherapeutics. In: Viness Pillay P, Chooona EPY, editors. *Advances in Neurotherapeutic Delivery Technologies*. Vol 8. UK: OMICS International; 2015.

37. Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. *Neuro-Oncology*. 2015;17(suppl 2):ii3–ii8.

38. Wang W, Sivakumar W, Torres S, et al. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. *Neurosurg Focus*. 2015;62(3):E8.

39. Ohlstest JR, Demorest ZL, Mootooa Y, et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the beauty Beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. *Molecular Therapy*. 2005;12(5):778–788.

40. Gillespie DL, Aguirre MT, Ravichandran S, et al. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model. *J Neurosurg*. 2015;122(2):331–341.

41. Huang J, Yuan D, Liu D, et al. Efficacy of antiangiogenic targeted immunotoxin DTAT and DTATEGF against glioblastoma multiforme. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. 2014;39(1):1–5.

42. Grossman R, Tyler B, Hwang L, et al. Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. *J Neurosurg*. 2011;28(4):1139–1146.

43. Schmidt NO, Ziu M, Carrabba G, et al. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. *Clin Cancer Res*. 2004;10(4):1255–1262.

44. Zagaroc D, Jakovec D, Gerebremin DH, Harder DR. Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. *J Cereb Blood Flow Metab*. 2008;28(8):1431–1439.

45. Clavreul A, Roger E, Pourbaghi-Masouleh M, Lemaire L, Téauté C, Menei P. Development and characterization of sorafenib-loaded lipid nanoparticles for the treatment of glioblastoma. *Drug Delivery*. 2018;25(1):1756–1765.

46. Sampson JH, Aakabani G, Archer GE, et al. Intracerebral infusion of an EGF receptor-targeted toxin in recurrent malignant brain tumors. *Neuro-Oncol*. 2008;10(3):320–329.
67. Menei P, Capelle L, Guyotat J, et al. Local and sustained delivery of.
65. Benny O, Kim S-K, Gvili K, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. *Hum Gene Ther*. 2003;14(9):883–895.
66. Chakroun RW, Zhang P, Lin R, Schiapparelli P, Quinones-Hinojosa A, Cui H. Nontherapeutic systems for local treatment of brain tumors. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2018;10(1):e1479.
68. Ong Q, Hochberg FH, Cima MJ. Depot delivery of dexamethasone and cediranib for the treatment of brain tumor associated edema in an intracranial rat glioma model. *J Controlled Release*. 2015;217:183–190.
69. Grayson ACR, Choi IS, Tyler BM, et al. Multi-pulse drug delivery from a resorbable polymeric microchip device. *Nat Mater*. 2003; 2(11):767–772.
70. Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. *J Controlled Release*. 2016;227:23–37.
71. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. *J Drug Target*. 2016;24(3):179–191.
72. Narayana A. Applications of nanotechnology in cancer: a literature review of imaging and treatment. *J Nucl Med Radiat Ther*. 2014; 95(4):195.
73. Tan YF, Lao LL, Xiong GM, Venkatraman S. Controlled-release nanotherapeutics: state of translation. *J Controlled Release*. 2018;284: 39–48.
74. Li Y, Li J, Woo YM, et al. Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model. *BMC Cancer*. 2017;17(1):126.
75. Sonabend AM, Veliciu S, Ulasov IV, et al. A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. *Anti-Cancer Drugs*. 2008;19(2):133–142.
76. Gasperini L, Mano JF, Reis RL. Natural polymers for the microencapsulation of cells. *J R Soc Interface*. 2014;11(100):20140817.
77. Gonzalez-Pujana A, Santos E, Orive G, Pedraz JL, Hernandez RM. Cell microencapsulation technology: current vision of its therapeutic potential through the administration routes. *J Drug Delivery Sci Technol*. 2017;42:49–62.
78. Olabisi RM. Cell microencapsulation with synthetic polymers. *J Biomed Mater Res*. 2015;103(2):846–859.
79. Opara EC. Applications of cell microencapsulation. *Methods Mol Biol Clifton NJ*. 2017;1479:23–39.
80. Shah K. Encapsulated stem cells for cancer therapy. *Biomatter*. 2013; 3(1):e24278.
81. Read T-A, Sorensen DR, Mahesperan R, et al. Local endothat treatment of gliomas administered by microencapsulated producer cells. *Nat Biotechnol*. 2001;19(1):29–34.
82. Bjerkvig R, Read TA, Vajkoczy P, et al. Cell therapy using encapsulated adult stem cells and adult stem cells for glioma therapy. *Biomaterials*. 2011; 32(8):2106–2116.
83. Choi SH, Tamura K, Khajuria RK, et al. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. *Mol Ther*. 2015;23(2):235–243.
84. de Boëard S, Guillamo J-S, Christov C, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. *Hum Gene Ther*. 2003;14(9):883–895.
85. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Js Y. The use of interleukin 12-secreting human neural stem cells for the treatment of intracranial glioma. *Acta Neurochir Suppl*. 2017;126:1255–1276.
86. Hadijargrou M, Chiu JB. Enhanced composite electropun nanofiber scaffolds for use in drug delivery. *Expert Opin Drug Deliv*. 2008;5(10): 1093–1106.
87. Nair RM. Applications of PLGA based nanostructures in drug delivery. *Colloids and Surfaces B: Biointerfaces*. 2001;19(1):29–34.
88. Cui H. Nanotherapeutic systems for local treatment of brain tumors. *Acta Neurochirurgica*. 2012;154(8):1379–1381.
89. Bow H, Hwang LS, Schildhaus N, et al. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. *J Neurosurg*. 2014;114(4): 662–669.
90. Frazier JL, Wang PP, Case D, et al. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. *J Neurooncol*. 2003;63(4):203–209.
91. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. *J Neurosurg*. 1995;48(4):635–640.
92. Ashby LS, Smith KA, Stea B. Gliadel wafer implantation combined with standard radiotherapy and concurrent follow up by adjacent tissue biopsy for treatment of newly diagnosed high-grade glioma: a systematic literature review. *World J Surg Onc*. 2016;14(1):225.
93. Martins C, Sousa F, Araujo F, Sarmento B. Functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications. *Adv Healthcare Mater*. 2018;7(11):1701035.
94. Mir M, Ahmed N, Rehman AU. Recent applications of PLGA based nanostructures in drug delivery. *Colloids and Surfaces B: Biointerfaces*. 2017;159:217–231.
95. Bow H, Hwang LS, Schildhaus N, et al. Local delivery of angiosuppressors combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. *J Neurosurg*. 2014;114(4): 662–669.
96. Frazier JL, Wang PP, Case D, et al. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. *J Neurooncol*. 2003;63(4):203–209.
97. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. *J Neurosurg*. 1995;48(4):635–640.
98. Martins C, Sousa F, Araujo F, Sarmento B. Functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications. *Adv Healthcare Mater*. 2018;7(11):1701035.
99. Mir M, Ahmed N, Rehman AU. Recent applications of PLGA based nanostructures in drug delivery. *Colloids and Surfaces B: Biointerfaces*. 2017;159:217–231.
100. Tseng Y-Y, Yang T-C, Wang Y-C, et al. Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. *Int J Nanomedicine*. 2017;12:1265–1276.
101. Hadijargrou M, Chiu JB. Enhanced composite electropun nanofiber scaffolds for use in drug delivery. *Expert Opin Drug Deliv*. 2008;5(10): 1093–1106.
102. Tseng Y-Y, Wang Y-C, Su C-H, et al. Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. *Int J Nanomedicine*. 2017;12:1265–1276.
103. Tseng Y-Y, Wang Y-C, Su C-H, et al. Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: in vitro and in vivo studies. *Colloids and Surfaces B: Biointerfaces*. 2015;134:254–261.
104. Lei C, Cui Y, Zheng L, Kah-Hoe Chow P, Wang C-H. Development of a gene/drug dual delivery system for brain tumor therapy: potent inhibition via RNA interference and synergistic effects. *Biomaterials*. 2013;34(30):7483–7494.
105. Tseng Y-Y, Su C-H, Yang S-T, et al. Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats using drug-loaded nanofibrous membranes. *Oncotarget*. 2016; 7(37):59902–59916.
106. Benny O, Kim S-K, Gvili K, et al. In vivo fate and therapeutic efficacy of PF-4/CTF microshres in an orthotopic human glioblastoma model. *Faseb J*. 2008;22(2):488–499.
107. Fodor JA, Galperin A, Ratner BD. Drug encapsulated polymeric microshres for intracranial tumor therapy: a review of the literature. *Adv Drug Deliv Rev*. 2015;91:23–37.
108. Menei P, Capelle L, Guyotat J, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microshres for the radiosensitization of malignant glioma: a randomized phase II trial. *Neurosurgery*. 2005;56(2):242–248.
92. van Eekelen M, Sasportas LS, Kasmieh R, et al. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. *Oncogene*. 2010;29(22):3185–3195.

93. Yang S-Y, Liu H, Zhang J-N. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. *DNA and Cell Biol*. 2004; 23(6):381–389.

94. Yin J, Kim J-K, Moon J-H, et al. hMSC-mediated concurrent delivery of endostatin and carboxyesterase to mouse xenografts suppresses glioma initiation and recurrence. *Mol Ther*. 2011;19(6):1161–1169.

95. Clavreul A, Lautram N, Franchini F, Montagu A, Lainé A-L. Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrocenophenol lipid nanocapsules. *JNFL* 2015;10:1259–1271.

96. Clavreul A, Pourbaghi-Masoule M, Roger E, Lautram N, Montero-Menei CN, Menei P. Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? *J Exp Clin Cancer Res*. 2017;36(1):135.

97. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. *Stem Cells Dev*. 2009;18(5):683–692.

98. Ramot Y, Steiner M, Morad V, et al. Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. *Nanotoxicology*. 2010;4(1):98–105.

99. Glover DJ, Lipsi HJ, Jans DA, Safe T. Towards safe, non-viral therapeutic gene expression in humans. *Nat Rev Genet*. 2005;6(4):299–310.

100. Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. *Mol Cancer*. 2017;16(1):31.

101. Sherman LS, Shaker M, Mariotti V, Rameshwar P. Mesenchymal stromal/stem cells as a pharmacological and therapeutic approach to accelerate glioma initiation and recurrence. *J Neurooncol*. 2015;122(1):1–10.

102. Shi Y, du L, Lin L, Wang Y. Tumour-associated mesenchymal/stromal cells in anticancer therapies. *J Cancer*. 2017;8(1):85–96.

103. Zhang C, Yang S-J, Wen Q, et al. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. *J Cancer*. 2017;8(1):11–19.

104. Bronckaers A, Hilkens P, Martens W, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. *Pharmaceutics*. 2014;143(2):181–196.

105. Merino-González C, Zubiaga FA, Escudero C, et al. Mesenchymal stem cell-derived extracellular vesicles promote angiogenesis: Potential clinical application. *Front Physiol*. 2016;7(999):24.

106. Roger M, Clavreul A, Sindjí L, et al. In vitro and in vivo interactions between glioma and marrow-isolated adult multilineage inducible (Miami) cells. *Brain Res*. 2012;1473:193–203.

107. Clavreul A, Etcheverry A, Tétaud C, et al. Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins. *J Neurooncol*. 2015;122(1):1–10.

108. Clavreul A, Guette C, Faguere R, et al. Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. *J Pathol*. 2014;233(1):74–88.

109. Clavreul A, Etcheverry A, Chassevent A, et al. Isolation of a new cell population in the glioblastoma microenvironment. *J Neurooncol*. 2012;106(3):493–504.

110. Appaix F, Nissou M-F, van der Sanden B, et al. Brain mesenchymal stem cells: The other stem cells of the brain? *World J Stem Cells*. 2014;6(2):134–143.

111. Hassain A, Gumni J, Gao F, et al. Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. *Stem Cells*. 2015;33(8):2400–2415.

112. Kong BHO, Shin H-DO, Kim SE-H, et al. Increased in vivo angiogenic effect of glioma stromal mesenchymal-stem-like cells on glioma cancer stem cells from patients with glioblastoma. *Int J OncoOncol*. 2013;42(5):1754–1762.

113. Lim E-J, Suh Y, Yoo K-C, et al. Tumor-associated mesenchymal stem-like cells provide extracellular signaling cue for invasiveness of glioblastoma cells. *OncoTarget*. 2017;8(1):1438–1448.

114. Svensson A, Ramos-Moreno T, Eberstål S, Scheding S, Bengzon J. Identification of two distinct mesenchymal stromal cell populations in human malignant glioma. *J Neurooncol*. 2017;131(2):245–254.

115. Shahar T, Rozovski U, Hess KR, et al. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. *Neuro Oncol*. 2017;19(5):660–668.

116. Yoon S-J, Shim J-K, Chang JH, et al. Tumor mesenchymal stem-like cell as a prognostic marker in primary glioblastoma. *Stem Cells International*. 2016;2016(1):1–7.

117. Argyriou AA, Giannopoulou E, Kalofonos HP. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. *Oncology*. 2009;77(1):1–11.

118. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA, Marrow-Derived B. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. *Gene Ther*. 2003;10(8):647–656.

119. Nolan DJ, Ciarciochi A, Mellick AS, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. *Genes Dev*. 2007;21(12):1546–1558.

120. Peters BA, Diaz LA, Polayk K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. *Nat Med*. 2005;11(3):261–262.

121. Wong MLH, Prawira A, Kaye AH, Hovens CM. Tumor angiogenesis: its mechanism and therapeutic implications in malignant gliomas. *J Clin Neurosci*. 2009;16(9):1119–1130.

122. Sonali, Viswanadh MK, Singh RP, et al. Nanotheranostics: emerging strategies for early diagnosis and therapy of brain cancer. *Nanotheranostics*. 2018;2(1):70–86.